Top Markets
Coin of the day
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.

HEPA
Rank in Stocks #39072
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is... Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Share Price
$0.073
Market Cap
$849.99K
Change (1 day)
4.29%
Change (1 year)
21.67%
Country
US
Trade Hepion Pharmaceuticals, Inc. (HEPA)

Category

Stock price history for Hepion Pharmaceuticals, Inc. (HEPA)
Highest end of day price: $0.06 on 2026-08-01

Lowest end of day price: $815.99K on 2014-02-01
Stock price history of Hepion Pharmaceuticals, Inc. from 2014 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) -13.45%
2025 -99.75%
2024 -83.90%
2023 -47.81%
2022 -72.98%
2021 -35.82%
2020 -64.66%
2019 -80.01%
2018 -87.43%
2017 -77.91%
2016 -3.97%
2015 1.80%
2014 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$504.83 29.34%
US
$839.07 28.61%
NL
$728.83 6.71%
CH
$1.07K -6.40%
KR
$252.06 11.35%
BE